Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistMyStart Health LLC sold compounded semaglutide products online while making false and misleading claims that characterized them as "Generic Ozempic" with "the same active ingredients and results" as FDA-approved products, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company's marketing claims were deceptive because compounded drugs are not FDA-approved and therefore cannot be equivalently marketed to prescription medications. By distributing these misbranded products through interstate commerce via their website, the company violated section 301(a) of the FDCA.